The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Apr. 10, 2017
Applicant:

Sutro Biopharma, Inc., South San Francisco, CA (US);

Inventors:

Christopher D. Thanos, Tiburon, CA (US);

Christopher J. Murray, Soquel, CA (US);

Junhao Yang, Palo Alto, CA (US);

Heather Stephenson, San Jose, CA (US);

Assignee:

Sutro Biopharma, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); C07K 14/245 (2006.01); C12P 21/06 (2006.01); C12N 1/21 (2006.01); C12N 15/00 (2006.01); C12P 21/00 (2006.01); C07K 16/00 (2006.01); C12P 21/02 (2006.01); C07K 16/06 (2006.01); C07K 16/32 (2006.01); C12N 9/52 (2006.01); C12Q 1/686 (2018.01); C12Q 1/689 (2018.01); G01N 30/02 (2006.01); G01N 30/06 (2006.01);
U.S. Cl.
CPC ...
C07K 14/245 (2013.01); C07K 16/00 (2013.01); C07K 16/065 (2013.01); C07K 16/32 (2013.01); C12N 9/52 (2013.01); C12P 21/00 (2013.01); C12P 21/02 (2013.01); C12Q 1/686 (2013.01); C12Q 1/689 (2013.01); G01N 30/02 (2013.01); G01N 30/06 (2013.01); C07K 2319/50 (2013.01); C12Y 304/00 (2013.01); C12Y 304/21 (2013.01);
Abstract

The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon.


Find Patent Forward Citations

Loading…